

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brad Sorensen

312-265-9574

bsorensen@zacks.com

scr.zacks.com

101 N. Wacker Drive, Chicago, IL 60606

Izotropic Corp

(IZOZF-OTC)

IZOZF: Expanding Market Opportunity

Izotropic is a medical device company with a potentially groundbreaking for device for detecting breast cancer. We value IZOZF at \$0.82 per share on a discounted cash flow analysis basis.

OUTLOOK

Izotropic is a medical device company that has developed an innovative machine that will allow for women to have more accurate and comfortable screenings for breast cancer.

The company announced it has come to an agreement to establish Izotropic Africa. This entity will provide access to an area that has over 200,000 cases of breast cancer annually and a mortality rate of over 50% due to delayed diagnosis and limited access to advanced care.

Current Price (02/17/26) \$0.16
Valuation **\$0.82**

SUMMARY DATA

52-Week High \$0.35
52-Week Low \$0.14
One-Year Return (%) N/A
Beta N/A
Average Daily Volume (sh) 41,778

Shares Outstanding (mil) 69
Market Capitalization (\$mil) \$11
Short Interest Ratio (days) N/A
Institutional Ownership (%) N/A
Insider Ownership (%) N/A

Annual Cash Dividend \$0.00
Dividend Yield (%) 0.00

5-Yr. Historical Growth Rates

Sales (%) N/A
Earnings Per Share (%) N/A
Dividend (%) N/A

P/E using TTM EPS N/A

P/E using 2025 Estimate N/A

P/E using 2026 Estimate N/A

Zacks Rank N/A

Risk Level

Type of Stock
Industry

High

Small

Medical Devices

ZACKS ESTIMATES

Revenue

(in millions of \$US)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2024	NA	NA	NA	NA	0 A
2025	0 A	0 E	0 E	0 E	0 E
2026	0 E	0 E	2 E	3 E	5 E
2027	2 E	2 E	3 E	3 E	10 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2024	NA	NA	NA	NA	-0.04 A
2025	0.00 A	-0.01 E	-0.01 E	-0.01 E	-0.03 E
2026	-0.01 E	0.00 E	0.02 E	0.02 E	0.03 E
2027	0.01 E	0.01 E	0.02 E	0.04 E	0.08 E

Update

Izotropic is an emerging medical device company aiming to transform breast imaging with its innovative IzoView Breast CT system. At its core, Izotropic's mission is straightforward but ambitious: to make breast cancer detection faster, clearer, and more comfortable for patients—particularly for the large number of women whose dense breast tissue makes traditional mammograms less effective. The company holds exclusive global rights to its technology from the University of California, Davis, where the underlying breast CT platform was developed over many years of academic research. With that foundation, Izotropic is now working to bring this technology to market through a dedicated imaging system that could redefine how clinicians see and diagnose breast cancer.

Izotropic represents a rare opportunity in an area that combines cutting-edge imaging innovation with a substantial unmet clinical need. The global market for breast imaging is growing steadily, and nearly half of women fall into the “dense breast” category, a demographic that standard mammography often struggles to serve. IzoView directly targets this challenge by producing true three-dimensional CT images of the breast without the painful compression required by traditional scans. This technology offers clearer visualization of tissue structure and lesions, which can potentially improve both detection rates and diagnostic confidence.

As mentioned, company management recognizes that breast cancer and issues with standard breast imaging access and quality exist across the world and has recently announced an agreement to establish an entity known as Izotropic Africa with an entity referred to as “a business group (BG)”. According to the company, the new entity intends to license, market, distribute, and evaluate manufacturing and/or assembly of IzoView Breast CT and certain follow-on products in all of Africa and the Gulf Cooperation Council: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.

This area has an urgent need for advanced breast cancer screening with estimates suggesting over 200,000 cases of breast cancer annually and mortality rates exceeding 50% due to delayed diagnoses and the limited access to advanced care many of the citizens have. Additionally, the company reports that the addressable market for advanced imaging devices is expected to exceed \$500 million by 2030.

The details of the agreement are that BG will hold a 60% interest and Izotropic will hold a 40% interest—subject to the final structure being agreed to by both parties by April 30, 2026. Other terms of the agreement indicated BG has committed to developing and executing an annual business plan focused on the sales, marketing, and distribution of IzoView and any follow-on products in Africa and the Gulf Cooperation Council. BG has also committed to securing a major hospital site in Morocco in Q1, 2026 for installation of an IzoView Breast CT Imaging System to serve as a research data collection and clinical study and approval location forming the foundation for regulatory engagement and market entry within the region, initiating approval processes with government health ministries in the designated territories, and assessing the feasibility of establishing manufacturing and/or assembly capabilities in Morocco to serve Africa and the Gulf area.


Lastly, the parties have agreed upon an estimated first-year start-up budget, pursuant to which Izotropic's 40% share is estimated at USD \$120K. Izotropic has agreed to advance 25% (USD \$30K) for the first three-month period against its portion of those estimated costs. All financial contributions and operational commitments of Izotropic beyond the initial capital advance remain subject to execution of the formal agreement and securing of financing.

For investors, Izotropic represents a higher-risk, high-potential opportunity that has a management that is clearly aggressively expanding its market opportunity. In our view, the company's valuation remains modest relative to the scale of the problem it is addressing and the potential impact of its technology. We believe this agreement is another sign that IZOZF is poised to moved higher as its superior technology begins to be distributed throughout the world—and investors with a higher risk tolerance should consider investing before the train leaves the station.

PROJECTED INCOME STATEMENT & BALANCE SHEET

Izotropic Income Statement and Balance Sheet								
(In thousands of US Dollars-Conversion rate: 1 Canadian dollar=0.72 US dollars)								
	2024A	1Q2025A	2Q2025E	3Q2025E	4Q2025E	2026E	2027E	
Revenue	0	0	0	0	0	5,000	10,000	
Cost of Goods Sold	0	0	0	0	0	1,000	2,000	
Profit margin	0	0	0	0	0	4,000	8,000	
Operating Expenses								
Consulting Fees	181	22	21	19	19	74	81	
Depreciation	35	8	9	10	11	42	44	
Filing and regulatory fees	47	4	4	4	5	19	20	
Research and development	490	105	116	127	140	560	588	
Other operating expenses	842	85	93	103	113	452	475	
Gross profit	(1,596)	(223)	(242)	(263)	(287)	2,853	6,792	
Interest	202	43	44	46	47	189	194	
Loan extension fees	0	36	0	6	0	0	0	
Other expenses	463	4	125	138	151	166	183	
Income/(Loss)	(2,260)	(306)	(412)	(453)	(485)	2,497	6,414	
Net Inc./ (Loss) Before Tax	(2,260)	(306)	(412)	(453)	(485)	2,497	6,414	
Income Tax Benefit/(Expense)	0	0	0	0	0	0	0	
Foreign Currency Translation	84	55	0	0	0	0	0	
Net Income/(Loss)	(2,344)	(306)	(412)	(453)	(485)	2,497	6,414	
Net Income/(Loss) per share	\$ (0.04)	\$ (0.00)	\$ (0.01)	\$ (0.01)	\$ (0.01)	\$ 0.03	\$ 0.08	
Diluted Common Shares Outstanding	58,684	61,618	64,699	67,934	71,331	74,897	78,642	
Current Assets								
Cash and cash equivalents	197	48	52	55	59	63	68	
Prepaid Expenses and deposits	82	90	90	90	90	90	90	
Other	5	6	5	5	5	5	5	
Total Current Assets	284	145	147	150	154	158	163	
Property, Plant and Equip.	14	6	6	6	6	6	6	
Other long-term assets	0	0	0	0	0	0	0	
Total other assets	14	6	6	6	6	6	6	
Total Assets	298	150	152	156	160	164	168	
Current Liabilities								
Accounts Payable and accrued liabilities	1,806	1,868	2,055	2,261	2,487	2,736	3,009	
Promissory notes	1,979	2,058	2,264	2,491	2,740	3,014	3,315	
Lease liabilities	11	3	3	3	4	4	5	
Total current liabilities	3,797	3,930	4,323	4,755	5,231	5,754	6,329	
Lease liability	0	0	0	0	0	0	0	
Other long-term liabilities	0	0	0	0	0	0	0	
Total long-term liabilities	0	0	0	0	0	0	0	
Total Liabilities	3,797	3,930	4,323	4,755	5,231	5,754	6,329	
Stockholders' equity/(deficit)	(3,498)	(3,779)	(4,171)	(4,599)	(5,071)	(5,590)	(6,161)	
Total Liabilities and Stockholders' Equity	298	150	152	156	160	164	168	

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.

SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover.

SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.